EUVIMEDEUVIMED entdecken
Open Access

Multiscale drug screening for cardiac fibrosis identifies MD2 as a therapeutic target

Hao Zhang, Phung N Thai, Rabindra V Shivnaraine, Lu Ren, Xuekun Wu, Dirk H Siepe, Yu Liu, Chengyi Tu, Hye Sook Shin, Arianne Caudal, Souhrid Mukherjee, Jeremy Leitz und 5 weitere

Cell · 2024-12 · 187 (25) · 7143-7163.e22

DOI: 10.1016/j.cell.2024.09.034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2024-12. Verfasst von Hao Zhang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Institute for Stem Cell Biology and Regenerative …. Hauptthemen laut MEDLINE: Fibrosis, Induced Pluripotent Stem Cells, Myocytes, Cardiac, Drug Evaluation, Preclinical. Die Arbeit wurde bisher 95-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Heart Association-American Stroke Association, NHLBI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FibrosisInduced Pluripotent Stem CellsMyocytes, CardiacDrug Evaluation, PreclinicalLymphocyte Antigen 96HumansAnimalsMiceFibroblastsSignal TransductionMyocardiumDisease Models, AnimalToll-Like Receptor 4MaleHeart FailureHigh-Throughput Screening AssaysMice, Inbred C57BLCell Proliferation

Stichwörter der Autor:innen

artesunatecardiac fibrosiscardiovasculardrug screeninginduced pluripotent stem cells

Substanzen

Lymphocyte Antigen 96Toll-Like Receptor 4

Autor:innen und Institutionen

  • Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305,…
  • Department of Internal Medicine, Division of Cardiovascular Medicine, University of California, Davis, Davis, CA 95616, USA; David Geffen School of Medicine at University of California, Los Angeles, CA 90095, USA.
  • Greenstone Biosciences, Palo Alto, CA 94305, USA.
  • Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Internal Medicine, Division of Cardiovascular Medicine, University of California, Davis, Davis, CA 95616, USA; Department of Basic Medical Sciences and Translational Cardiovascular Research Center, Univers…

Förderung

  • American Heart Association-American Stroke Association
  • NHLBI NIH HHS
  • NIH HHS
  • NCRR NIH HHS
  • National Institutes of Health
  • TRDRP
  • American Heart Association Inc
  • U.S. Department of Defense

Zitieren

APA

Zhang, H., Thai, P. N., Shivnaraine, R. V., Ren, L., Wu, X., Siepe, D. H., Liu, Y., Tu, C., Shin, H. S., Caudal, A., Mukherjee, S., Leitz, J., Wen, W. T. L., Liu, W., Zhu, W., Chiamvimonvat, N., & Wu, J. C. (2024). Multiscale drug screening for cardiac fibrosis identifies MD2 as a therapeutic target. Cell, 187(25), 7143-7163.e22. https://doi.org/10.1016/j.cell.2024.09.034

Vancouver

Zhang H, Thai PN, Shivnaraine RV, Ren L, Wu X, Siepe DH, et al. Multiscale drug screening for cardiac fibrosis identifies MD2 as a therapeutic target. Cell. 2024;187(25):7143-7163.e22. doi:10.1016/j.cell.2024.09.034

BibTeX
@article{Zhang2024,
  author = {Zhang, Hao and Thai, Phung N and Shivnaraine, Rabindra V and Ren, Lu and Wu, Xuekun and Siepe, Dirk H and Liu, Yu and Tu, Chengyi and Shin, Hye Sook and Caudal, Arianne and Mukherjee, Souhrid and Leitz, Jeremy and Wen, Wilson Tan Lek and Liu, Wenqiang and Zhu, Wenjuan and Chiamvimonvat, Nipavan and Wu, Joseph C},
  title = {Multiscale drug screening for cardiac fibrosis identifies MD2 as a therapeutic target},
  journal = {Cell},
  year = {2024},
  volume = {187},
  number = {25},
  pages = {7143--7163.e22},
  doi = {10.1016/j.cell.2024.09.034}
}
Kostenlos starten →